PCR London Valves 2016 opened in the main arena with the Edwards Lifesciences TNT session “TAVI in 2016: the year the treatment of aortic stenosis was transformed.” It was announced during the session that the Edwards SAPIEN 3™ transcatheter heart valve has received CE Mark approval for use in intermediate-risk patients.
The Edwards SAPIEN 3™ valve made headlines at London Valves 2016, with EU approval for intermediate-risk patients announced during the opening night TNT session.
The Tools and Techniques session focused on how the Edwards SAPIEN 3™ transcatheter heart valve is transforming the treatment of aortic stenosis, through impactful clinical evidence, streamlined patient pathways and procedures, and the promise of future innovations.
Visit SAPIEN3.com to learn more about intermediate-risk data with the SAPIEN 3™ valve.
